CatchMe Therapeutics is developing a novel class of drugs targeting epitranscriptomic modifiers

Scientific approach

Epitranscriptomic modifications and their respective modifier enzymes affect important RNA processing steps such as splicing, translation and stability. M6A is the most abundant mRNA modification, and its modifying enzymes have been found to play an important role in various cancers, influencing propagation, survival and other processes. CatchMe is initially targeting an M6A “writer” enzyme.

link to CatchMe Therapeutics page




Vladislav Krupalnik, PhD – Co-Inventor

Shay Geula, PhD – Co-Inventor

Yael Tsalenchuck, PhD – CSO

Scroll to top